Catecholamine synthesis and metabolism pathway

The catecholamine synthesis and metabolism pathway is the biochemical sequence responsible for the production and degradation of key neurotransmitters, specifically dopamine and noradrenaline (Source: StatPearls NBK459154). This process begins with the rate-limiting enzyme tyrosine hydroxylase, which converts L-tyrosine to L-DOPA, followed by the action of aromatic L-amino acid decarboxylase to produce dopamine (Source: UniProt P07101). In noradrenergic neurons, dopamine is further converted to noradrenaline by dopamine beta-hydroxylase (Source: UniProt P09172). Turnover is regulated by metabolic enzymes, primarily monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), which break down these neurotransmitters into metabolites like homovanillic acid (HVA) and vanillylmandelic acid (VMA) (Source: PubMed 15554234). This pathway is a critical therapeutic focus for numerous neurological and psychiatric conditions, such as Parkinson's disease and ADHD (Source: PubMed 19364998). Pharmacological interventions include enzyme inhibitors like selegiline and entacapone, precursors like levodopa, and vesicular depleting agents like reserpine (Source: PubChem). Because these neurotransmitters regulate mood, movement, and autonomic function, pharmacological manipulation requires careful management to avoid side effects such as dyskinesia or hypertensive crises (Source: PubMed 21185312). Monitoring metabolites provides clinical insight into the pathway's activity and the efficacy of therapeutic interventions (Source: PubMed 15554234).

Other names

Dopamine and noradrenaline synthesis/turnoverCatecholamine turnoverMonoamine synthesis and degradationCatecholamine biosynthetic pathway

Modulation of catecholamine levels through the inhibition of biosynthetic enzymes (e.g., tyrosine hydroxylase), metabolic enzymes (e.g., MAO, COMT), or vesicular storage (VMAT2), and the provision of metabolic precursors (e.g., L-DOPA).